 |
|
Anti-hypertensive drugs may help prevent and treat Alzheimer's disease
October 26, 2007A new study has identified commonly prescribed drugs for the treatment of hypertension may be capable of preventing Alzheimer�s disease and cognitive deterioration.
The new research, published in the November 2007 issue of the The Journal of Clinical Investigation., conducted by Dr. Giulio Maria Pasinetti, M.D., Ph.D., Professor of Psychiatry and Neuroscience, Geriatrics and Adult Development and Director of the Center of Excellence for Research in Complementary and Alternative Medicine in Alzheimer's disease at Mount Sinai School of Medicine, suggests that a large number of geriatric patients currently under pharmacological treatment for high-blood pressure with certain anti-hypertensive drugs might reap the additional benefits of the drug's cognitive effects.
"If we can deliver certain anti-hypertensive drugs to patients at high risk to develop Alzheimer�s disease, at doses that do not affect blood pressure, these drugs could be made available for all members of the geriatric population identified as being at high risk for developing Alzheimer's disease," said Dr. Pasinetti.
Study Results
Over the past two years, investigators directed by Dr. Pasinetti at Mount Sinai have been screening more than 1,500 drugs that are already commercially available for treatment of other disorders, to determine their potential value in treating Alzheimer's disease and cognitive impairment.
Based on the outcomes from initial drug screening, Dr. Pasinetti and his collaborators identified 7out of 55 candidate drugs commonly prescribed for the treatment of hypertension, which are capable of significantly preventing beta-amyloid production, which is a major mechanism recently identified as playing a key role in Alzheimer's disease pathogenesis, particularly in respect to promotion of memory loss and dementia. In this new study, Dr. Pasinetti reports that mice genetically determined to develop Alzheimer�s disease beta-amyloid production and subsequent cognitive deterioration, significantly benefit from the treatment with the anti-hypertensive agent Valsartan, found to pharmacologically prevent beta-amyloid production in the brain even when delivered to Alzheimer� disease mice at doses 3-4 fold lower than the minimal equivalent dose prescribed for the treatment of hypertension in humans. Other anti-hypertension drugs with beneficial results included Propranolol HCI, Carvedilol, Losartan, Nicardipine HCI, Amiloride HCI and Hydralazine HCI.
Showing the use of anti-hypertensive drugs with anti- beta-amyloid production activities in the brain of Alzheimer� disease mice, will help in the identification of future, novel disease- modifying pharmacological treatments for the prevention of cognitive deterioration and eventually dementia in Alzheimer's disease.
Future Research
Dr. Pasinetti recognizes the limitations of the research, noting that studies must be immediately verified in human subjects to verify the effect of the drugs on cognitive deterioration and memory functions independent of their role as an anti-hypertensive agent.
"The use of these drugs for their potential anti-Alzheimer�s disease role is still highly experimental, and at this stage we have no clinical data beyond phenomenological observation in humans" said Dr. Pasinetti. "We need to complete preventive and therapeutic clinical trials in the near future if we are to identify certain anti-hypertensive drugs with anti beta-amyloid antioligomeric activities, which will need to be prescribed at dosages that do not interfere with blood pressure in normotensive Alzheimer�s disease patients."
Dr. Pasinetti's research is part of a growing push to identify and develop more effective treatments for Alzheimer's disease. This devastating, degenerative illness is of particular concern for baby boomers beginning to turn 60, at increased risk of developing cognitive deterioration and Alzheimer's disease.
The Mount Sinai Hospital / Mount Sinai School of Medicine
Study Results
Over the past two years, investigators directed by Dr. Pasinetti at Mount Sinai have been screening more than 1,500 drugs that are already commercially available for treatment of other disorders, to determine their potential value in treating Alzheimer's disease and cognitive impairment.
Based on the outcomes from initial drug screening, Dr. Pasinetti and his collaborators identified 7out of 55 candidate drugs commonly prescribed for the treatment of hypertension, which are capable of significantly preventing beta-amyloid production, which is a major mechanism recently identified as playing a key role in Alzheimer's disease pathogenesis, particularly in respect to promotion of memory loss and dementia. In this new study, Dr. Pasinetti reports that mice genetically determined to develop Alzheimer�s disease beta-amyloid production and subsequent cognitive deterioration, significantly benefit from the treatment with the anti-hypertensive agent Valsartan, found to pharmacologically prevent beta-amyloid production in the brain even when delivered to Alzheimer� disease mice at doses 3-4 fold lower than the minimal equivalent dose prescribed for the treatment of hypertension in humans. Other anti-hypertension drugs with beneficial results included Propranolol HCI, Carvedilol, Losartan, Nicardipine HCI, Amiloride HCI and Hydralazine HCI.
Showing the use of anti-hypertensive drugs with anti- beta-amyloid production activities in the brain of Alzheimer� disease mice, will help in the identification of future, novel disease- modifying pharmacological treatments for the prevention of cognitive deterioration and eventually dementia in Alzheimer's disease.
Future Research
Dr. Pasinetti recognizes the limitations of the research, noting that studies must be immediately verified in human subjects to verify the effect of the drugs on cognitive deterioration and memory functions independent of their role as an anti-hypertensive agent.
"The use of these drugs for their potential anti-Alzheimer�s disease role is still highly experimental, and at this stage we have no clinical data beyond phenomenological observation in humans" said Dr. Pasinetti. "We need to complete preventive and therapeutic clinical trials in the near future if we are to identify certain anti-hypertensive drugs with anti beta-amyloid antioligomeric activities, which will need to be prescribed at dosages that do not interfere with blood pressure in normotensive Alzheimer�s disease patients."
Dr. Pasinetti's research is part of a growing push to identify and develop more effective treatments for Alzheimer's disease. This devastating, degenerative illness is of particular concern for baby boomers beginning to turn 60, at increased risk of developing cognitive deterioration and Alzheimer's disease.
The Mount Sinai Hospital / Mount Sinai School of Medicine
Anti-hypertensive Current Events and Anti-hypertensive News RSSReducing salt intake can lower blood pressure
Adults who use less salt in their diet can experience a slight reduction in their blood pressure in the medium term.
Some blood pressure drugs may help protect against dementia, study shows
A particular class of medication used to treat high blood pressure could protect older adults against memory decline and other impairments in cognitive function, according to a newly published study from Wake Forest University School of Medicine.
Why African-Americans are at greater risk of hypertension and kidney disease
Physician-scientists from NewYork-Presbyterian Hospital/Weill Cornell Medical Center believe that a heightened level a certain growth factor in the blood may explain why blacks have a greater prevalence of hypertension and kidney disease compared to whites.
Atrial fibrillation in endurance athletes still poses problems for sports cardiologists
The fulfilment which so many people increasingly derive from competitive sports and endurance training comes with a real - even if rare - twist.
Overweight male teens with normal blood pressures showing signs of heart damage
AUGUSTA, Ga. - Even while their blood pressures are still normal, overweight male teens may have elevated levels of a hormone known to increase pressures as well as early signs of heart damage, researchers say.
Blood pressure compound may benefit brain tumor patients
A widely used blood pressure medication may be the key to preventing brain function loss common after radiation treatment, according to a newly published study by researchers at Wake Forest University Baptist Medical Center. The findings offer the hope of an improved quality of life for cancer patients.
Study finds treatment fails to improve common form of heart failure
A medication used for high blood pressure does not improve a common form of heart failure, according to new results from a large, international study.
Angiotensin receptor blockers are lower incidence, progression of Alzheimer's disease
Researchers at Boston University School of Medicine (BUSM) have, for the first time, found that angiotensin receptor blockers (ARBs)-a particular class of anti-hypertensive medicines-are associated with a striking decrease in the occurrence and progression of dementia. Data from this study will be presented this weekend (July 27) at the 2008 International Conference on Alzheimer's disease in Chicago.
Rheumatoid arthritis is a risk factor for cardiovascular disease
The risk of cardiovascular disease (CVD) for people with rheumatoid arthritis (RA) has been found to be comparable to the risk of CVD in people with type 2 diabetes.
Study shows pine bark naturally reduces cardiovascular risk factors in diabetics
A new study published in the May 2008 (volume 8, issue 25) edition of the journal of Nutrition Research shows Pycnogenol (pic-noj-en-all), an antioxidant plant extract from the bark of the French maritime pine tree, reduces blood sugar in type II diabetes patients, allows people to lower their antihypertensive medication and improves cardiovascular disease (CVD) risk factors.
More Anti-hypertensive Current Events and Anti-hypertensive News Articles
|
Prazosin, evaluation of a new anti-hypertensive agent: Proceedings of a symposium held at the Centre interprofessionnel, Geneva, 8 March, 1974 by American Elsevier (Publisher) | |
 |
Anti-Hypertensive Tea, Natural Chinese Herb Tea by China Harbin Yeekong Herb Inc. Anti-Hypertensive Tea, Natural Chinese Herb Tea The item have passed through the recognition of GMP, health food with GMP 100% Natural It is a natural drink for those who want to adjust their blood pressure and keep it in a healthy condition. Ingredients: Cassia seed, self-heal, uncaria, motherwort fruit, scutellaria, and green tea. Function & Indication: Specially for hypertension, earringing & restlessness caused by hypertension, clear up internal heat, cooling, eye-brightening, improving the liver and lowering hypertension. Features: *Contains no sugar *No artificial colors *No preservatives *No flavors Specification:2g x 20 bags/box, 100 boxes/carton Expiry Period: 24 months, keep in a cool and dry place. Produce Date: July 1st , 2009 |
|
Anti-Hypertensive Drugs (International Encyclopedia of Pharmacology and Theraputics) by Doyle (Author) | |
|
The effects of four anti-hypertensive agents upon the performance of normal subjects on driving-related skills (Departmental report) by A. B Clayton (Author) | |
|
The effects of four anti-hypertensive agents upon the performance of normal subjects on driving-related skills (Departmental report - Department of Transportation ... Planning, University of Birmingham ; no. 48) by Andrew Barham Clayton (Author) | |
 |
Antihypertensive Therapy: Principles & Practice (An International Symposium) by F. Gross (Editor) |
| © 2009 BrightSurf.com |